UNSPSC 51271602: Bumecaine

This classification denotes an anesthetic agent with the molecular formula C18H28N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B77K612SPZ, chemically known as 2-pyrrolidinecarboxanilide, 1-butyl-2,4,6-trimethyl- but generally known as bumecaine, which bears US NIH Compound Identifier 65770. Bumecaine most often comes in base and hydrochloride forms. European Medicines Agency schedules Bumecaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05969MIG.

UNSPSC 51271602 Bumecaine, a Commodity code, encompasses local anesthetic pharmaceutical products that state and local government health systems and procurement cooperatives source through multi-vendor frameworks. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP posted January 20, 2026, illustrates the primary procurement activity under this code: state and local health departments, hospital systems, and emergency services purchase bumecaine and related local anesthetics as part of broader generic pharmaceutical and over-the-counter product contracts. Issuing bodies include state health agencies participating in cooperative purchasing vehicles like MMCAP, which coordinates procurement across multiple states including Minnesota and Oregon. Vendors responding to this code must meet stringent regulatory compliance including cGMP certification and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with authorized wholesalers such as AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and carry professional liability insurance of at least $2,000,000.

The MMCAP RFP, due March 26, 2026, represents the recent opportunity set under this code. Responding vendors must submit detailed product information including NDC codes, SKUs, UPCs, strength, dosage form, and manufacturing locations in designated Excel format converted to CSV, with pricing evaluated on a 75 percent weight for price competitiveness, 10 percent for fixed pricing over the contract term, and 5 percent each for administrative fee data compliance, EDI capability, and agreement to a 3 percent administrative fee. Contract awards will be effective July 1, 2026, with terms of two years for new responders and optional extensions at MMCAP's discretion. No specific set-aside designations or dollar values are disclosed in the available documentation. Performance obligations include late-reporting penalties of $200 to $1,500 per violation and compliance with FDA requirements, including minimum six-month shelf life with at least one year from manufacture.